Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joe Gn Garcia
University of Arizona, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Aqualung Therapeutics, Corp.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The Financial Entity is a privately held, for-profit company engaged in the principal business activity of medical therapeutics research and development. The Investigator has declared that he is founder, President, CEO, and Board Chairman of the Financial Entity and holds an equity stake in the Financial Entity. The financial Entity licenses Intellectual Property related to the research. Accordingly, the research results could affect the value of the Financial Entity of related interest.
Novel Involvement of NAMPT and TLR4 in PAH Vascular Remodeling
RELEVANCE Pulmonary arterial hypertension (PAH) is a progressive disease caused by functional and structural changes in the pulmonary vasculature, which lead to increased pulmonary vascular resistance and, eventually right ventric- ular failure and death. Despite recent advances, there remains a need for improved understanding of PAH path- ophysiology and a need for improved therapeutic options for these patients, as current therapies are severely limited. We have proposed the cytokine/enzyme, nicotinamide phosphoribosyltransferase (NAMPT), and its re- ceptor, Toll like receptor 4 (TLR4), as novel therapeutic targets. NAMPT promotes vascular cell resistance to apoptosis, cell proliferation, and smooth muscle cell survival, all processes implicated in pulmonary vascular remodeling. We hypothesize that NAMPT may play an important role in PAH pathobiology.
Filed on April 05, 2019.
Tell us what you know about Joe Gn Garcia's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.